Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL ( The 42nd Annual Meeting of the European...)

Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL

The 42nd Annual Meeting of the European Association for the Study of the Liver

PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for the treatment of hepatitis C (HCV) will be made during the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) being held in Barcelona, Spain from April 11-15, 2007. The PSI-6130 studies were conducted through Pharmasset's HCV collaboration with Roche. Dr. Phillip Furman, Pharmasset's Vice President of Biological Sciences, will be presenting Pharmasset's posters beginning on Thursday, April 12, 2007 at 7:00pm (CEST). The complete abstracts can be viewed at http://www.easl.ch/liver-meeting.

Clevudine is Efficiently Phosphorylated to the Active Triphosphate form in Human Hepatocytes

    C. Niu 1, E. Murakami 1, M.J. Otto 1, P.A. Furman 1

    1 Pharmasset, Inc., Princeton, NJ, USA

    Study subject:  initial half-life of the clevudine triphosphate.

Inhibition of HCV Replication by PSI-6130: Characterization of Activity in the HCV Replicon System

W.R. Jiang 1, S. Ali 1, S. Le Pogam 1, C. Daniel 1, S. Chiu 1, T. Kretz 1, I. Najera 1, P. Furman 2, N. Cammack 1, J. Symons 1

1 Roche Palo Alto LLC, Palo Alto, CA, USA; 2 Pharmasset Inc., Princeton, NJ, USA

Study subject: inhibition of HCV replication using combinations of PSI- 6130 with other HCV inhibitors.

Inhibition of HCV Replication by PSI-6130: Mechanism of Biochemical Activation and Inhibition

P.A. Furman 1, E. Murakami 1, H. Bao 1, J. Symons 2, M.J. Otto 1

1 Pharmasset, Inc., Princeton, NJ, USA; 2 Roche Palo Alto LLC, Palo Alto, CA, USA

Study subject: investigation of the enzymes involved in the phospho
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

( The 42nd Annual Meeting of the European...)Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL,Health